(19)
(11) EP 3 825 306 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.08.2023 Bulletin 2023/31

(45) Mention of the grant of the patent:
07.06.2023 Bulletin 2023/23

(21) Application number: 20200633.4

(22) Date of filing: 30.04.2008
(51) International Patent Classification (IPC): 
C07D 221/28(2006.01)
A61K 31/439(2006.01)
 C07B 59/00(2006.01)
A61P 11/14(2006.01)
(52) Cooperative Patent Classification (CPC):
C07B 59/002; C07D 471/08; A61K 31/195; A61K 31/4709; A61K 31/485; A61K 31/49; C07D 221/28; G01N 33/491; G01N 33/493; A61P 11/00; A61P 11/14; A61P 25/00

(54)

MORPHINAN COMPOUNDS

MORPHINANVERBINDUNGEN

COMPOSÉS DE MORPHINANE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 01.05.2007 US 91513007 P
08.05.2007 US 91666207 P
28.09.2007 US 97604407 P

(43) Date of publication of application:
26.05.2021 Bulletin 2021/21

(60) Divisional application:
22199041.9 / 4183787

(62) Application number of the earlier application in accordance with Art. 76 EPC:
19201663.2 / 3632916
17206213.5 / 3357923
16163718.6 / 3093290
14173190.1 / 2792662
11000764.8 / 2357183
08747238.7 / 2152709

(73) Proprietor: Sun Pharmaceutical Industries, Inc.
Princeton, NJ 08540 (US)

(72) Inventor:
  • TUNG, Roger
    Lexington, Massachusetts 02420 (US)

(74) Representative: Marks & Clerk LLP 
15 Fetter Lane
London EC4A 1BW
London EC4A 1BW (GB)


(56) References cited: : 
   
  • G. HEINKELE ET. AL.: "Synthesis of [2H3]-dextromethorphan and its major urinary metabolites [2H3]-dextrorphan and [2H3]-dextrorphan-beta-glucoronide", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 45, 2002, pages 1153-1158, XP002490642, DOI: 10.1002/jlcr.640
  • T.H. EICHHOLD ET. AL.: "Highly sensitive high-peformance liquid chromatographic-tandem mass spectrometric method for the analysis of dextromorphan in human plasma.", JOURNAL OF CHROMATOGRAPHY B, vol. 698, 1997, pages 147-154, XP002490644,
  • G. HEINKELE ET. AL.: "Synthesis of [2H]-labelled phase I metabolites using 1-[2H]-pyridinium hydrochloride.", JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS, vol. 48, 2005, pages 457-461, XP002490645, DOI: 10.1002/jlcr.941
  • H. BÖLCSKEI ET. AL.: "Synthesis of deuterated dextromethorphan derivatives.", ARKIVOK, vol. 2008, no. iii, 1 March 2008 (2008-03-01), pages 182-193, XP002490643,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).